Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

PM3B > Insulin formulation and delivery > Flashcards

Insulin formulation and delivery Flashcards

1
Q
  1. What are biomacromolecules/biologics
A

Biomacromolecules used as drugs – rather than small molecules

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q
  1. What are the differences between small molecule and therapeutic proteins
A

Small molecule:
Molecule weight - <500g/M
Chemical nature – carbon chain – organic
Complexity – low homogenous
Delivery – site of action

Therapeutic protein
Molecule weight - >100g/M
Chemical nature – hydrophilic polypeptide – organic
Complexity – high single protein moderate heterogeneity
Delivery – site of action

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q
  1. What are examples of small molecules and biologicals
A

Small molecule – aspirin
- Biologicals – monoclonal antibody and flu vaccine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q
  1. What are the 4 categories of biologicals And examples (?)
A
  • Gene therapy – nucleic acid ( Gendicine )
  • Protein and peptides – polypeptide (Insulin, Growth hormone, Clotting/blood factors)
  • Monoclonal antibodies – polypeptide (Herceptin (Trastuzumab), MabThera (Rituximab), Remicade (Infliximab))
  • Vaccine – mixture of lipids, polypeptides, nucleic acids ( Influenza vaccine, BCG tuberculosis vaccine, Hepatitis B vaccine)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q
  1. What are the challenges for all biologicals
A
  • Complexity of biologics higher than typical drugs
  • Instability of biomacromolecules inherent due to biological origin
  • Availability often limited by large molecular size
  • Immunogenicity immune response to drug (hypersensitivity) can lead to loss of efficacy and more serious adverse effects
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q
  1. Why is the complexity of biologics often higher than typical small molecule drugs
A
  • Molecular complexity
  • Functional complexity
  • Complex composition
  • More to go wrong- more expensive to manufacture
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q
  1. Why are biologics typically so unstable?
A
  • Instability of biomacromolecules inherent due to biological origin
  • Conditions must be compatible with biological molecules
  • BUT this means they are good food for microbes – or at least in a good environment
  • Also, many reactions of biological molecules are thermodynamically favourable in these conditions
  • Finally, almost all Biologics contain proteins- and proteins are relatively unstable
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q
  1. What is more unstable
A
  • Protein
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q
  1. What is the mechanism of protein instability?
A

1) Proteins have three-four layers of vital structure
2) Basic polypeptide chain is susceptible to a range of degrading reactions with water and oxygen
3) Many changes are irreversible

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q
  1. What is the importance of protein structure
A
  • Denatured proteins – won’t work, often irreversible
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q
  1. Delivery of biologics – availability often limited by large molecular size
    how does it access
A

Permeability through epithelia
- Access to tissues from blood vessels
- Cell membranes *although drug target usually noy within cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q
  1. What are the common problems of delivery of biologics
A
  • Common problem- oral delivery unsuitable
  • Different route for each class/example
  • Route typically used is dictated by the characteristics of each class
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q
  1. How is biomacromolecules delivered usually?
A
  • In common
  • Biomacromolecules won’t pass through epithelia or membranes
  • Digested by gastric and intestinal components
  • Oral biomacromolecules = food!
  • Typically can’t use oral delivery => “PARENTERAL”
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q
  1. What are the formulation and delivery areas of protein/insulin?
A

Formulation and delivery areas:
- Protein sequence (& source)
- Physical state of protein (phase, crystallinity)
- Subcutaneous delivery devices
- Alternative routes of administration

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q
  1. What are the 2 main classes of therapeutic proteins
A

a. Proteins and peptides - Closest replacement of endogenous proteins
b. Monoclonal antibodies - Ability to bind any antigen target Range of effects- blocking, binding, activating, killing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q
  1. Production of pharmaceutical protein – methods
A

Production of pharmaceutical proteins
1: Biotechnology
* Protein examples: insulin, erythropoietin, monoclonal antibodies, cytokines and interferons
* Produced in microbial or animal cell cultures and isolated via chromatographic and filtration steps
2: Isolate from blood (or animal tissue)
* Protein examples: albumin and blood clotting factors
* Protein isolation focused on reduction of viral contamination

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q
  1. What are the problems of biotechnology and isolating from blood to produce protein?
A

Bio tech
Problems:
Produce in microbes: non-mammalian protein
Produce in animal cells: high cost

Isolate
Problems:
Purify from animals- non-human sequence
Purify from humans- viral infection, BSE prion infection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q
  1. Why is insulin The most intensely researched therapeutic macromolecule
A

Large number of diabetics – market pull
Long term (lifetime) treatment – ease to use
Precise, continuous delivery needed – dose control
Dire consequence of failure to deliver- vital therapy

19
Q
  1. What are the different insulin options?
A

Rapid-acting
- Short-acting
- Intermediate-acting
- Long-acting

20
Q
  1. What is used in type 1 diabetes to treat it?
A

Type 1, insulin-dependent, autoimmune, child onset diabetes
- Precise, continuous delivery needed: replacing pancreatic glycaemic control

21
Q
  1. What is used in type 2 diabetes to treat it?
A
  • Type 2, “adult onset” noninsulin-dependent diabetes
  • Supplementary extra insulin provided to prevent harm from high blood glucose
22
Q
  1. What are the different types of insulin?
A

1: Purified animal insulin
Oldest form of insulin
Still available: porcine (pig) and bovine (cow; rare use

2: Technological breakthrough for recombinant DNA technology:
- “Recombinant” human insulin
- Variants of human insulin have now been genetically engineered (altered amino acid sequence) with changes to speed of onset and duration of activity

23
Q
  1. Give examples of rapid- acting insulins and means ?
A
  • Onset of action of 15 minutes; Duration of 2-5 hours
  • Insulin lispro (Humalog®),
  • insulin aspart (NovoRapid®),
  • insulin glulysine (Apidra®)
24
Q
  1. how does insulin aspart modification work?
A
  • Insulin aspart – position B28 proline replaced with negatively charged aspartic acid = faster dissociation of hexamer
25
Q
  1. What is long acring insulins and what are examples of them?
A
  • Longer effect than intermediate-acting insulins; Normally used once daily to maintain a constant level of insulin (steady state achieved after 2-4 days). Examples:
  • Insulin glargine (Lantus®)
  • Insulin detemir (Levemir®)
  • Insulin degludec (Tresiba®)
26
Q
  1. How does insulin glargine modification work?
A
  • Asparginine residue substituted with glargine at position 21 of A chain = stabilise hexamer interactions
  • Add 2 arginine residues on C-terminus of B chain = less soluble at pH of subcutaneous tissue
27
Q

what allows tuning of kinetics of insulin release? ( diff physical forms of insulin)

A

Modification of aggregation, quaternary structure and crystallinity alters solubility and availability: allows tuning of kinetics of insulin release

Changes in rapidity of onset and duration

28
Q

when insulin is injected subcutaneously what is formed?

A

depot

Lowest molecular weight monomeric insulin is most rapidly released
Dissociation of aggregates/crystals/complexed insulin results in slow release of active therapeutic

29
Q

different forms of insulin - physical form:

A

Insulin protein can have different quaternary structures
i.e. 6 single insulin protein molecules forms complex with zinc

6-mer is ‘stored form’ – also has slower release after injection

Single molecule is ‘active form’ – but is released faster

30
Q

what does 6-mer mean

A

6-mer is ‘stored form’ – also has slower release after injection

31
Q

what is single molecule mean

A

Single molecule is ‘active form’ – but is released faster

32
Q

what are the Three basic regimes for T1D

A

One, two or three insulin injections per day of a short-acting or rapid-acting insulin analogue with an intermediate-acting insulin
Multiple daily injections. A short-acting or rapid-acting insulin analogue is injected before meals, together with one or more separate daily injections of an intermediate-acting insulin or a long-acting insulin.
Continuous sub-cutaneous insulin infusion. A programmable pump delivers a regular or continuous amount of insulin (usually short-acting or rapid-acting insulin analogue) via a SC needle or cannula.

33
Q

Insulin regimes are individualised for each patient
true or false

A

true

34
Q

delivery of insulin ( availability)

A

Availability of protein drugs limited by large molecular size

Common problem- oral delivery unsuitable
Different route for each class/example

Route typically used is dictated by the characteristics of each class, and clinical need
INSULIN:
can be infused intravenous (i.v.) – not practical for everyday use
can be subcutaneous (s.c.)
Depends on clinical need- i.v. infusion in hospital only, for acute treatment. In community, routine treatment, s.c. injection

35
Q

what devices are used for insulin administration?

A

Pre-filled injectors or
Solution for injection plus
- syringe and needle
- Injectors, autoinjectors
- Needle-free injectors
- Pumps
Needle disposal needed

36
Q

how should insulins be stored?

A

For almost all insulins:
(including pre-filled injectors,
solution for injection)

Protein solutions not stable at elevated temperatures

37
Q

what are the potential future for insulin?

A

1- Needle-free injectors
2- Inhaled

development
3- Transdermal
4- Oral

38
Q

what are the advantages and disadvantages of needle free inhectors

A

Advantages: no more needles, many happy users

Disadvantages: supply, complex to use, bruising

39
Q

what is pulmonary delivery of insulin?

A

Joint development between Aventis and Pfizer, Exubera was an inhaled short-acting insulin preparation indicated for the treatment of type 1 and type 2 diabetes.
The approval of the world’s first inhaled insulin marked an important advance in the treatment of diabetes.
Product failed to gain acceptance from both patients and clinicians.

40
Q

what are the challenges with transdermal insulin delivery

A

Cream:
Challenge:
Low bioavailability through skin
-high molecular weight
-hydrophilic

Assuming permeability barrier overcome, precise dosing impossible with cream.

Watches :
Holy grail: real-time transdermal glucose monitoring and insulin dosing
Delivery challenge x2:
glucose measured from blood/ insulin delivery into blood

Further challenges:
-reactivity/dermatitis
-cost
-reliability
-complex user requirements

41
Q

oral insulin

A

protein = food
Market pull drives experimental attempts:
e.g. microencapsulation to protect from gastric/intestinal degradation

Further challenges:
?mechanism of absorption of microencapsulated protein?

42
Q

artifical pancreas

A

All the technology is available to replace the pancreas
Blood glucose monitors
Mini-pumps with cannula delivery
Computation and wearable electronics

43
Q

Summary
Drug Class: Proteins and peptides
General challenges for formulation and delivery of proteins.
Protein sequence, physical form, both used to control PK

Insulin formulation and delivery:
Many routes explored, some achieved, but subcutaneous injection remains dominant.
Different physical and protein sequence forms of insulin have differing pharmacokinetic properties.
Examples of possible routes explored for insulin include injection, needle-free injection, inhaled, transdermal and oral

A

PM3B (29 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions